MONICA DUBE: Open Payments
NPI 1417058801 · BURLINGTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,056 in 9 payments from 8 companies in 2025. Trend: 2023 $698 · 2024 $937 · 2025 $1,056
Food & beverage: $1,056
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $198 |
| Alnylam Pharmaceuticals Inc. | 1 | $146 |
| Madrigal Pharmaceuticals | 1 | $140 |
| HEARTFLOW, INC. | 1 | $133 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| GlaxoSmithKline, LLC. | 1 | $109 |
| ABBVIE INC. | 1 | $107 |
| ACADIA Pharmaceuticals Inc | 1 | $101 |
Products named: REXULTI, AMVUTTRA, REZDIFFRA, FFRct, AIRSUPRA, BLUJEPA, SKYRIZI, NUPLAZID.
Industry payments across MA — which companies pay providers there.
